SCHEMBL4344210

SCHEMBL4344210

CCOC(=O)CCn1cc(-c2cccnc2)c2nc[nH]c(=O)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.43
LMNA P02545 2/20 0.42
POLB P06746 2/20 0.42
CYP3A4 P08684 3/20 0.39
CYP2C19 P33261 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
MCL1 Q07820 1/20 0.38
TBXAS1 P24557 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
TUBB4A P04350 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335098 0.94 BRD4 (0.41) BRD4LMNAPOLBCYP3A4CYP2C19
SCHEMBL4337751 0.82 BRD4 (0.41) BRD4MCL1TBXAS1HSD17B10
SCHEMBL4330619 0.77 GAA (0.43) LMNAPOLBCYP3A4CYP2C19MEN1
SCHEMBL4334996 0.77 DHPS (0.52) BRD4CYP3A4CYP2C19ALDH1A1CYP2E1
SCHEMBL4344213 0.75 KMT2A (0.50) LMNACYP3A4CYP2C19KMT2ACYP1A2
SCHEMBL4332652 0.75 GAA (0.41) LMNAPOLBMEN1KMT2ATBXAS1
SCHEMBL4325319 0.72 TNF (0.43) LMNARAB9AKDM4EHPGDHSD17B10
SCHEMBL4325482 0.71 POLB (0.44) LMNAPOLBCYP3A4CYP2C19MEN1
SCHEMBL22086127 0.71 SRC (0.52) BRD4LMNAMEN1KMT2ANPC1
SCHEMBL3938582 0.69 KDM4E (0.42) POLBCYP2C19MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661897-B1 PYRROLOPYRIMIDINONE DERIVATIVE TEIJIN PHARMA LTD (JP) 2013-12-04 EP disclosed
US-7557113-B2 Substituted pyrrolo[3,2-d]pyrimidine derivatives TEIJIN PHARMA LIMITED (JP) 2009-07-07 US disclosed
US-7557113-B2 Substituted pyrrolo[3,2-d]pyrimidine derivatives TEIJIN PHARMA LIMITED (JP) 2009-07-07 US disclosed
US-7557113-B2 Substituted pyrrolo[3,2-d]pyrimidine derivatives TEIJIN PHARMA LIMITED (JP) 2009-07-07 US disclosed
US-20060160831-A1 Pyrrolopyrimidinone derivatives TEIJIN PHARMA LIMITED (JP) 2006-07-20 US disclosed
EP-1661897-A1 PYRROLOPYRIMIDINONE DERIVATIVE Teijin Pharma Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160831-A1 Pyrrolopyrimidinone derivatives GSK3B, GSK3A, GSKIP BRD4 351/4885LMNA 863/4885POLB 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.